Dergiler / Turkish Journal of Internal Medicine / 2021 / Cilt: 3 - Sayı: 3

The correlation of tumor markers, neutrophil/lymphocyte ratio and FDG PET/CT measures in pancreatic cancer

Sayfa
95–101
Yayın Tarihi
2021-07-29
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Diagnosing and following up malignities should be supported by other laboratory technics and imaging methods.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective:This review will outline the correlation of tumor markers and NLR (Neutrophil/lymphocyte ratio) with measures such as MTV (mean total volume), TLG (total lesion glycolysis), and SUV (standart uptake value) in 18F FDG PET/CT in pancreatic carcinoma with the goal of selection of appropriate treatment modality and decrease rates of treatment failure and recurrences in pancreatic carcinoma by using tumor markers.
📊
Temel Bulgular & Veri:Methods:45 patients that new diagnosed pancreatic cancer were included in the study.
💡
Sonuç & Katkı:Diagnosing and following up malignities should be supported by other laboratory technics and imaging methods.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:CA 19.9 · CEA · AFP

Abstract

Objective:This review will outline the correlation of tumor markers and NLR (Neutrophil/lymphocyte ratio) with measures such as MTV (mean total volume), TLG (total lesion glycolysis), and SUV (standart uptake value) in 18F FDG PET/CT in pancreatic carcinoma with the goal of selection of appropriate treatment modality and decrease rates of treatment failure and recurrences in pancreatic carcinoma by using tumor markers. In this way, we can predict the results of imaging modalities, using easy lab technics such as NLR and tm markers. Methods:45 patients that new diagnosed pancreatic cancer were included in the study. Diagnosis were confirmed by cytology. Their tumor marker levels (CA 19.9, CEA and AFP), NLR and PET/CT measurements (SUVmax, SUVmean, TLG, MTV) were obtained. Patients that already diagnosed, followed up or treated by oncology department, were excluded. Results:When tumor markers were compared with PET/CT measurements (SUVmax, SUVmean, TLG, MTV and tumor size) there were no significant difference between them. Also, total uptake values of organs (liver, spleen, pancreas) were not related with tm marker levels. However, there were positive significant correlation between tumor size and SUVmax, SUVmean, TLG (p=0.02 r = 0.347, p=0.022 r = 0.340, p=0.008 r =0.392). Conclusions:Tumor markers may help diagnosing or managing of pancreatic malignities, but we cannot predict PET/CT results according to tumor marker levels. So, tumor markers must be used as an adjunctive method for diagnosing malignities. They cannot be major determiner for malignities. Diagnosing and following up malignities should be supported by other laboratory technics and imaging methods.

Anahtar kelimeler
🔖

Bu Makaleye Atıf Yap

HAFIZOĞLU, M., KOROGLU, R., DEMİR, H., BOZKURT, E., HAFIZOĞLU, E. (2021). The correlation of tumor markers, neutrophil/lymphocyte ratio and FDG PET/CT measures in pancreatic cancer. Turkish Journal of Internal Medicine, Cilt: 3 - Sayı: 3, 95–101. https://ajindex.com/articles/809034

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254 2. Karaman M. Pankreatik kanserde susturulan CA9 ve TSPAN8 genlerinin etkilerinin in vitro ve in vivo olarak araştırılması. Doktora Tezi. Balıkesir: Balıkesir Üniversitesi Fen Bilimleri Enstitüsü, Biyoloji Anabilim Dalı, 2018. 3. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990 Apr;85(4):350-5. 4. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007 Apr;33(3):266-70. doi: 10.1016/j.ejso.2006.10.004. 5. Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Barlett DL, Zureikat AH, Bahary N, Zeh HJ. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol 2014 Dec;21:4351-8. doi: 10.1245/10434-014-3842-z. 6. Ito S, Gejyo F. Elevation of serum CA19-9 levels in benign diseases. Intern Med 1999 Nov;38(11):840-1. doi: 10.2169/internalmedicine.38.840. 7. Tempero MA, Uchida E, Takasaki H, Burnett AD, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987 Oct;15;47(20):5501-3. 8. Gold P, Freedman SO. Specific carcinoembryonic antigen of human digestive system. J Exp Med 1965 Sep;1;122(3):467-81. 9. Blumenthal RD, Hansen HJ, Goldenberg DM. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res 2005 Oct 1;65(19):8809-17.doi: 10.1158/0008-5472.CAN-05-0420. 10. Hostetter RB, Augustus LB, Mankarious R, Chi K, Fan D, Toth C, Thomas P, Jessup JM. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst 1990 Mar 7;82(5):380-5. 11. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K,Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989 Apr 21;57(2):327-34. doi: 10.1016/0092-8674(89)90970-7. 12. Pignatelli M, Durbin H, Bodmer WF. Carcinoembryonic antigen functions as an accessory adhesion molecule mediating colon epithelial cell-collagen interactions. Proc Natl Acad Sci 1990 Feb;87(4):1541-5. doi: 10.1073/pnas.87.4.1541. 13. Medoff JR, Jegasothy BV, Roche JK. Carcinoembryonic antigen-induced release of a suppressor factor from normal human lymphocytes in vitro. Cancer Res 1984